Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer

Abstract Background Basket clinical trials targeting the KRASG12C-mutation in solid tumors have shown initial promise, including in orphan KRASG12C head and neck cancer (HNC). However, development of resistance to KRASG12C-mutant-specific inhibitors (KRASG12Ci) remains a major obstacle. Here, we inv...

Full description

Saved in:
Bibliographic Details
Main Authors: Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M. Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben-Lulu, Baisali Bhattacharya, Angel Porgador, Dexin Kong, Johannes Brägelmann, J. Silvio Gutkind, Moshe Elkabets
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
KRASG12C mutation
Adagrasib
Sotorasib
Drug resistance
Cell-autonomous
Tumor microenvironment
Online Access:https://doi.org/10.1186/s13046-024-03227-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-024-03227-0

Similar Items